Antibodies News and Research

RSS
COVID-19 CG tracks local SARS-CoV-2 mutations by geographical location

COVID-19 CG tracks local SARS-CoV-2 mutations by geographical location

New SARS-CoV-2 B.1.526 variant emerges in New York

New SARS-CoV-2 B.1.526 variant emerges in New York

Free-ranging minks exhibit high titers of SARS-CoV-2 antibodies in Utah

Free-ranging minks exhibit high titers of SARS-CoV-2 antibodies in Utah

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers investigate the duration of the immune response to SARS-CoV-2

Researchers investigate the duration of the immune response to SARS-CoV-2

Programmed magnetic nanobeads rapidly diagnose COVID-19

Programmed magnetic nanobeads rapidly diagnose COVID-19

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

UC San Diego receives $33 million from NIH for five COVID-19 diagnostic projects

UC San Diego receives $33 million from NIH for five COVID-19 diagnostic projects

Research shows effective strategy to target the SARS-CoV-2 spike protein

Research shows effective strategy to target the SARS-CoV-2 spike protein

Research shows how antibodies attach to and block Zika virus

Research shows how antibodies attach to and block Zika virus

Study reports lasting immune response in convalescent COVID-19 patients

Study reports lasting immune response in convalescent COVID-19 patients

Anti-phospholipid antibodies in severely ill patients not distinctive to COVID-19, says study

Anti-phospholipid antibodies in severely ill patients not distinctive to COVID-19, says study

Study of children hospitalized with COVID-19 shows 2% mortality

Study of children hospitalized with COVID-19 shows 2% mortality

'Miracle poison' can target a variety of different proteins

'Miracle poison' can target a variety of different proteins

Lab study of South African SARS-CoV-2 variant and Moderna vaccine: reduced neutralization, but still protective

Lab study of South African SARS-CoV-2 variant and Moderna vaccine: reduced neutralization, but still protective

Full characterization of mammalian-produced SARS-CoV-2 receptor binding domains

Full characterization of mammalian-produced SARS-CoV-2 receptor binding domains

Study shows antibody responses persisting 10 months after SARS-CoV-2 infection

Study shows antibody responses persisting 10 months after SARS-CoV-2 infection

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.